Clinical trial NCT04903444: Development and Validation of an Artificial Intelligence-based Biliary Stricture Navigation System in MRCP-based ERCP
Official title: A Single-center Study on the Effectiveness and Safety of Artificial Intelligence Assisted System in Clinical Application of Endoscopic Retrograde Cholangiopancreatography
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gastrointestinal Disease
Endoscopy
Artificial Intelligence
Endoscopic Retrograde Cholangiopancreatography
Lead sponsor: Renmin Hospital of Wuhan University
Sponsor class: OTHER
First posted: 2021-05-26
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, the investigators proposed an artificial intelligence-based biliary stricture navigation system in MRCP-based ERCP, which can instruct the direction of guide wire and the position of stent placement in real time.

Detailed description: 585/5000 Biliary stricture can be divided into benign biliary stricture and malignant biliary stricture, and malignant hilar biliary obstruction is the one of the common cause. Since there is no specific early screening method for malignant hilar biliary obstruction at present and most patients have no obvious clinical symptoms in the early stage, most patients are already in the advanced stage when they are first diagnosed. Advanced malignant hilar biliary obstruction cannot undergo resection surgery, whose first choice for the treatment is palliative endoscopic biliary drainage.Biliary drainage can relieve jaundice, pruritus and other symptoms due to cholestasis. However,before the narrow segment was placed the stent, the contrast agent could not pass through the narrow segment and the bile duct above the narrow segment could not be seen.So it was difficult for doctors to determine the direction of the guide wire and the position of the stent. In addition, indiscriminate application of the contrast agent may cause outflow obstruction leading to infection. However, there is no relevant research to solve these problems.

MRCP is the preferred examination method of pancreatic and bile duct diseases. Therefore, MRCP should be routinely performed before patients are treated with ERCP. At present, MRCP is in supine position, and ERCP is in prone position. Different positions lead to differences in the morphology of MRCP and the bile duct on ERCP.So preoperative MRCP in supine position has limited role in advising physicians on the morphology of the bile duct. Therefore, MRCP in the prone position is more favorable for endoscopists to perform ERCP .

In recent years, deep learning algorithms have been continuously developed and increasingly mature.They have been gradually applied to the medical field. Computer vision is a science that studies how to make machines "see". Through deep learning, camera and computer can replace human eyes to carry out machine vision such as target recognition, tracking and measurement.Interdisciplinary cooperation in the field of medical imaging and computer vision is also one of the research hotspots in recent years. At present, it is mainly applied to the automatic identification and detection of lesions and quality control, and has achieved good results. It can assist doctors to find lesions, make disease diagnosis and standardize doctors' operations, so as to improve the quality of doctors' operations.With mature technical support, it has a good prospect and application value to develop endoscopic operating system for lesion detection and quality control based on artificial intelligence methods such as deep learning.

In this study, the investigators proposed an artificial Intelligence-based Biliary Stricture Navigation System in MRCP-based ERCP, which can instruct the direction of guide wire and the position of stent placement in real time.

Eligibility criteria: Inclusion Criteria:

1. Bile duct segmentation model 1) Male or female aged 18 or above; 2) Who needs ERCP,MRCP and its related tests are needed to further define the characteristics of digestive tract diseases； 3)The images of MRCP and ERCP are clear; 4) Able to read, understand and sign informed consent; 5) The investigator believes that the subject can understand the process of the clinical study and is willing and able to complete all the study procedures and follow-up visits and cooperate with the study procedures.
2. Bile duct matching model

In addition to the criteria mentioned in the bile duct segmentation model, the bile duct matching model should also meet the following criteria:

1. Able to complete MRCP in prone position;
2. Bile ducts are almost completely visible in MRCP and ERCP.

(3) Clinical trials

In addition to the criteria mentioned in the bile duct segmentation model, the clinical trials should also meet the following criteria:

1. Able to complete MRCP in prone position;
2. Patients requiring biliary drainage by ERCP due to malignant hilar biliary obstruction.

Exclusion Criteria:

1. Bile duct segmentation model and bile duct matching model 1)Has participated in other clinical trials, signed the informed consent and was in the follow-up period of other clinical trials; 2) Drug or alcohol abuse or psychological disorder in the last 5 years; 3) Patients in pregnancy or lactation; 4) The investigator considers that the subjects were not suitable for MRCP, ERCP and related tests; 5)A high-risk diseases or other special conditions that the investigator considers inappropriate for the subject to participate in a clinical trial；
2. Clinical trials

In addition to the criteria mentioned in the above, the clinical trial must not meet any of the following criteria:

1. Previous gastrectomy;
2. Stent replacement;
3. Pyloric or duodenal obstruction.

Primary outcomes:
measure: Procedure time
timeFrame: During procedure
Secondary outcomes:
measure: Intersection over Union of bile duct segmentation
timeFrame: A month
measure: Intersection over union of bile duct matching model:
timeFrame: 6 month
measure: Success rate of stent placement
timeFrame: During procedure
measure: Rate of adverse events
timeFrame: Until discharge assessed up to 14 days
measure: Fluoroscopy time
timeFrame: During procedure
measure: Total amount of contrast medium
timeFrame: During procedure
measure: The difference of the area of bile duct visualization in different position
timeFrame: During procedure
measure: The difference in the time required to perform MRCP in different position
timeFrame: During procedure
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin hospital of Wuhan University
state: Hubei
Study officials:
affiliation: Renmin Hospital of Wuhan University
name: Honggang Yu Yu, Doctor
role: PRINCIPAL_INVESTIGATOR
References: